ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01228682
Recruitment Status : Unknown
Verified April 2013 by Otsuka Frankfurt Research Institute GmbH.
Recruitment status was:  Active, not recruiting
First Posted : October 26, 2010
Last Update Posted : May 1, 2013
Sponsor:
Information provided by (Responsible Party):
Otsuka Frankfurt Research Institute GmbH

Brief Summary:

A Drug Utilisation Survey is performed to monitor and document the drug utilisation patterns of Samsca in routine medical practice.

A Post-Authorisation Safety Study is performed to collect information on the safety of Samsca when used in a real-life setting.


Condition or disease Intervention/treatment
SIADH Non-SIADH Hyponatremia Non-Hyponatremia Drug: Tolvaptan

Detailed Description:

Drug Utilisation Survey The drug utilisation analysis will describe the number of prescriptions, their distribution between different medical specialties, and indication for use as compared to the SmPC, patient age and patient gender distributions on a prescription level. In addition, the indication for use will be further categorised as

  • SIADH
  • Non-SIADH hyponatraemia
  • Non-Hyponatraemia

Post-Authorisation Safety Study

Sodium levels at baseline and rate of sodium correction under therapy will be analysed. Safety findings will be described. The number of all non-serious and serious adverse events and the relative frequencies will be analysed in consideration of the risk categories below:

  • Renal safety
  • Aquaresis-related adverse effects
  • Serum sodium correction rate
  • Glucose homeostasis
  • Cardiovascular safety and hemodynamics
  • Respiratory system
  • Drug metabolism and drug interactions
  • Drug exposure during pregnancy
  • Paediatric safety

Subgroup analyses will be performed for all safety findings by indication subgroups (SIADH and other indications), subgroups according to SIADH-underlying diseases, age groups, hepatically impaired patients and renally impaired patients.


Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multi-Centre, Multi-National, Observational Post-Authorisation Safety Study to Document the Drug Utilisation of Samsca and to Collect Information on the Safety of Samsca When Used in Routine Medical Practice
Study Start Date : October 2010
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Tolvaptan
U.S. FDA Resources

Group/Cohort Intervention/treatment
Patients who are treated with Samsca. Drug: Tolvaptan
Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
Other Name: Samsca



Primary Outcome Measures :
  1. Drug utilisation of Samsca stratified by prescribing medical specialty, indication for use, patient gender and patient age. [ Time Frame: 3 years ]
  2. Samsca sodium correction rates and adverse events in patients treated with Samsca [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are treated with Samsca
Criteria

Inclusion Criteria:

  • Patients who are treated with Samsca

Exclusion Criteria:

  • Patients who have not signed the data consent form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01228682


  Hide Study Locations
Locations
Denmark
Otsuka Study location 45-001
Copenhagen, Denmark
Otsuka Study location 45-006
Holstebro, Denmark
Germany
Otsuka Study location 49.007
Aachen, Germany
Otsuka Study location 49.016
Dresden, Germany
Otsuka Study location 49.011
Duesseldorf, Germany
Otsuka Study location 49.002
Hamburg, Germany
Otsuka Study location 49.012
Hannover, Germany
Otsuka Study location 49.018
Hannover, Germany
Otsuka Study Location 49-020
Heidelberg, Germany
Otsuka Study location 49-024
Heidelberg, Germany
Otsuka Study location 49.004
Koeln, Germany
Otsuka Study location 49.009
Luebeck, Germany
Otsuka Study location 49.017
Mannheim, Germany
Otsuka Study location 49-019
Regensberg, Germany
Otsuka Study location 49-021
Rostock, Germany
Otsuka study location 49-001
Wuerzburg, Germany
Italy
Otsuka Study location 39-001
Cuneo, Italy
Otsuka Study location 39.007
Florence, Italy
Otsuka Study location 39.005
Siena, Italy
Norway
Otsuka Study location 47-001
Lorenskog, Norway
Spain
Otsuka Study location 34-007
Alicante, Spain
Otsuka Study location 34-014
Castellon, Spain
Otsuka Study location 34-015
Castellon, Spain
Otsuka Study location 34-013
Cordoba, Spain
Otsuka Study location 34-005
Madrid, Spain
Otsuka Study location 34.017
Majadahonda, Spain
Otsuka Study location 34-002
Sevilla, Spain
Otsuka Study location 34-012
Sevilla, Spain
Sweden
Otsuka Study Location 46.001
Goeteborg, Sweden
Otsuka Study location 46-004
Karlstad, Sweden
Otsuka Study location 46.002
Linköping, Sweden
Otsuka Study location 46-003
Stockholm, Sweden
United Kingdom
Otsuka Study location 44.024
Birmingham, United Kingdom
Otsuka Study location 44.019
Coventry, United Kingdom
Otsuka Study location 44.003
Durham, United Kingdom
Otsuka Study location 44-023
Hartlepool, United Kingdom
Otsuka Study location 44.005
Kingston, United Kingdom
Otsuka Study location 44.006
Liverpool, United Kingdom
Otsuka Study location 44.016
Liverpool, United Kingdom
Otsuka Study location 44-001
Manchester, United Kingdom
Otsuka Study location 44.007
Manchester, United Kingdom
Otsuka Study location 44.013
Manchester, United Kingdom
Otsuka Study location 44.021
Nuneaton, United Kingdom
Otsuka Study location 44-027
Oldham, United Kingdom
Otsuka Study location 44.015
Oldham, United Kingdom
Otsuka Study location 44-025
Preston, United Kingdom
Otsuka Study location 44.004
Southampton, United Kingdom
Sponsors and Collaborators
Otsuka Frankfurt Research Institute GmbH

Responsible Party: Otsuka Frankfurt Research Institute GmbH
ClinicalTrials.gov Identifier: NCT01228682     History of Changes
Other Study ID Numbers: 156-09-101
First Posted: October 26, 2010    Key Record Dates
Last Update Posted: May 1, 2013
Last Verified: April 2013

Keywords provided by Otsuka Frankfurt Research Institute GmbH:
Sodium
SIADH
Hyponatremia
Vasopressin
Salt
Water

Additional relevant MeSH terms:
Hyponatremia
Water-Electrolyte Imbalance
Metabolic Diseases
Tolvaptan
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs